GSK 5959

Pricing Availability   Qty
Cat.No. 5385 - GSK 5959 | C22H26N4O3 | CAS No. 901245-65-6
Description: Potent and selective BRPF1 inhibitor
Chemical Name: N-[2,3-Dihydro-1,3-dimethyl-2-oxo-6-(1-piperidinyl)-1H-benzimidazol-5-yl]-2-methoxybenzamide
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (6)

Biological Activity for GSK 5959

GSK 5959 is a potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. Inhibits BRPF1 interaction with histone H3.3. Cell permeable.

External Portal Information for GSK 5959

Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of GSK 5959 is reviewed on the chemical probes website.

Technical Data for GSK 5959

M. Wt 394.47
Formula C22H26N4O3
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 901245-65-6
PubChem ID 15990224
InChI Key LTUGYAOMCKNTGG-UHFFFAOYSA-N
Smiles CN(C1=CC(NC(C4=C(OC)C=CC=C4)=O)=C(N3CCCCC3)C=C1N2C)C2=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for GSK 5959

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 3.94 10 with sonication

Preparing Stock Solutions for GSK 5959

The following data is based on the product molecular weight 394.47. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 25.35 mL 126.75 mL 253.5 mL
0.5 mM 5.07 mL 25.35 mL 50.7 mL
1 mM 2.54 mL 12.68 mL 25.35 mL
5 mM 0.51 mL 2.54 mL 5.07 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for GSK 5959

References are publications that support the biological activity of the product.

Demont et al (2014) 1,3-dimethyl benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain. ACS Med.Chem.Lett. 5 1190 PMID: 25408830


If you know of a relevant reference for GSK 5959, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Bromodomain Inhibitors

Keywords: GSK 5959, GSK 5959 supplier, GSK5959, potent, selective, BRPF1, bromodomains, inhibitors, inhibits, cell, permeable, Bromodomains, 5385, Tocris Bioscience

Citations for GSK 5959

Citations are publications that use Tocris products.

Currently there are no citations for GSK 5959. Do you know of a great paper that uses GSK 5959 from Tocris? Please let us know.

Reviews for GSK 5959

There are currently no reviews for this product. Be the first to review GSK 5959 and earn rewards!

Have you used GSK 5959?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Research Product Guide

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Stem Cell Research Product Guide

Stem Cell Research Product Guide

This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:

  • Self-renewal and Maintenance
  • Differentiation
  • Reprogramming
  • Organoid Generation
  • GMP and Ancillary Material Grade Products
Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Epigenetics Research Bulletin

Epigenetics Research Bulletin

Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:

  • Bromodomains
  • DNA Methyltransferases
  • Histone Deacetylases
  • Histone Demethylases
  • Histone Methyltransferases
Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.